Norditropin Nordiflex (Somatropin)

Somatropin, the active ingredient in Norditropin Nordiflex, is a human growth hormone presented as an injectable solution for subcutaneous use. It treats growth hormone deficiency and related growth disorders in children and adults.

GNH USA supplies Norditropin Nordiflex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Norditropin Nordiflex is a recombinant human growth hormone indicated for several endocrine and growth‑related conditions. - Growth hormone deficiency in children: supports linear growth and improves height velocity. - Turner syndrome: promotes growth and helps achieve a more typical stature. - Prader‑Willi syndrome: enhances growth and body composition. - Chronic renal insufficiency associated growth failure: aids in catch‑up growth. - Short stature due to idiopathic causes: stimulates growth when other causes are excluded. - Adult growth hormone deficiency: improves body composition, bone density and quality of life.

Common Side Effects: - Injection site pain or erythema. - Headache. - Joint or muscle discomfort. - Peripheral edema. - Transient hyperglycemia. - Nausea.

Serious or Rare Side Effects: - Intracranial hypertension (headache, visual changes). - Slipped epiphysis or rapid bone growth leading to pain. - Allergic reactions including anaphylaxis. - Tumor recurrence or progression in patients with a history of malignancy.

Before initiating therapy, clinicians should consider several safety aspects. - Monitor glucose levels: somatropin can affect carbohydrate metabolism. - Assess for signs of intracranial hypertension: persistent headaches warrant evaluation. - Evaluate skeletal health: rapid growth may exacerbate scoliosis or slipped epiphysis. - Adjust dose in renal impairment: clearance may be altered. - Avoid use in active malignancy: growth hormone may stimulate tumor growth. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Somatropin may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - High‑dose glucocorticoids: antagonize growth‑hormone effects. - Insulin therapy: increased risk of hypoglycemia. - Oral hypoglycemic agents: may require dose adjustment.

Moderate Interactions (Monitor Closely): - Estrogen therapy: can alter IGF‑1 levels. - Thyroid hormone replacement: requires monitoring of thyroid status. - Other growth‑factor products: potential additive effects on growth.